- Pre-market US stocks experienced notable movements driven by corporate earnings, asset sales, and business mergers.
- NetEase shares rose 7.14 % following its strong Q2 2026 financial report with 30,100,000,000 yuan in net revenue and subsequent target price upgrades.
- RF Acquisition Corp II surged 405.81 % after shareholders approved a business merger, while Werewolf Therapeutics gained 130.43 % from a platform sale and licensing deal.
- Sunshine Guojian released its 2026 interim report, recording RMB 866 million in total operating revenue and RMB 371 million in net profit attributable to equity holders.
- The company advanced its R&D pipeline and secured approvals for products including Yisaituo® and Yisaina®, while expanding global clinical trials through external collaboration.
- This performance reflects robust financial growth and strategic progress, reinforcing the company's market position in antibody therapeutics and autoimmune diseases.